Insider at

04

Insider transactions

05
0 buys (P) 0 sells (S) Net: $0 + 9 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

9 other filings hidden
DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
April 10, 2018 VYGR S 10b5-1 2,451 $18.38 $45,049 0 Direct -100.00% Disposed -86.7% (price as of 2026-10-02)
March 12, 2018 VYGR S 10b5-1 2,451 $25.16 $61,667 2,451 Direct -50.00% Disposed -90.3% (price as of 2026-10-02)
Feb. 12, 2018 VYGR S 10b5-1 2,451 $18.24 $44,706 4,902 Direct -33.33% Disposed -86.6% (price as of 2026-10-02)
Jan. 10, 2018 VYGR S 10b5-1 3,630 $16.40 $59,532 7,353 Direct -33.05% Disposed -85.1% (price as of 2026-10-02)
Dec. 11, 2017 VYGR S 10b5-1 5,490 $13.63 $74,829 10,983 Direct -33.33% Disposed -82.0% (price as of 2026-10-02)
Nov. 10, 2017 VYGR S 10b5-1 5,490 $13.26 $72,797 16,473 Direct -25.00% Disposed -81.5% (price as of 2026-10-02)
Oct. 10, 2017 VYGR S 10b5-1 10,980 $20.33 $223,223 21,963 Direct -33.33% Disposed -87.9% (price as of 2026-10-02)
Sept. 11, 2017 VYGR S 10b5-1 10,980 $14.30 $157,014 32,943 Direct -25.00% Disposed -82.9% (price as of 2026-10-02)
Sept. 5, 2017 VYGR S 10b5-1 5,490 $10.00 $54,900 17,157 Direct -24.24% Disposed -75.5% (price as of 2026-10-02)
July 20, 2017 VYGR S 10b5-1 5,490 $10.00 $54,900 49,413 Direct -10.00% Disposed -75.5% (price as of 2026-10-02)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.

06
DateTickerSecurityUnderlying Exercise priceExpirationSharesA/D
June 22, 2022 PRAX Stock Option (Right to Buy) Common Stock (65,000) $2.12 June 22, 2032 65,000 Acquired
Jan. 7, 2022 PRAX Stock Option (Right to Buy) Common Stock (77,000) $18.11 Jan. 7, 2032 77,000 Acquired
Feb. 12, 2021 PRAX Stock Option (Right to Buy) Common Stock (65,800) $52.53 Feb. 12, 2031 65,800 Acquired
Jan. 4, 2021 PRAX Stock Option (Right to Buy) Common Stock (45,000) $2.27 Oct. 18, 2028 45,000 Disposed
March 7, 2018 VYGR Stock Option (Right to Buy) Common Stock (65,000) $28.72 March 7, 2028 65,000 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 11 holdings

07

Securities held when first becoming an insider, per SEC Form 3.

DateTickerSecuritySharesOwnership
Oct. 15, 2020 PRAX Common Stock 11,021 Direct
Oct. 15, 2020 PRAX Stock Option (Right to Buy)→ Common Stock (184,479) 184,479 Direct
Oct. 15, 2020 PRAX Stock Option (Right to Buy)→ Common Stock (80,507) 80,507 Direct
Oct. 15, 2020 PRAX Stock Option (Right to Buy)→ Common Stock (93,457) 93,457 Direct
July 7, 2017 VYGR Common Stock 117,647 Direct
July 7, 2017 VYGR Stock Options (Right to Buy)→ Common Stock (11,364) 11,364 Direct
July 7, 2017 VYGR Stock Options (Right to Buy)→ Common Stock (5,882) 5,882 Direct
July 7, 2017 VYGR Stock Options (Right to Buy)→ Common Stock (401) 401 Direct
July 7, 2017 VYGR Stock Options (Right to Buy)→ Common Stock (24,599) 24,599 Direct
July 7, 2017 VYGR Stock Options (Right to Buy)→ Common Stock (11,942) 11,942 Direct
July 7, 2017 VYGR Stock Options (Right to Buy)→ Common Stock (53,058) 53,058 Direct

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2015 $309,000 $35,000 · $88,513 $77,250 · · $474,763

PRAX

M.D.Former Chief Medical Officer(5)
Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2022 $287,249 $416,667 · · · · $402,314 $2,763,754
2021 $466,667 · · · $285,000 · $18,838 $4,509,171
2020 $425,000 · · · $357,000 · $17,813 $1,711,010

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.